Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

6 november 2026 bijgewerkt door: Novartis Pharmaceuticals

A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).

Studie Overzicht

Gedetailleerde beschrijving

This is a global, phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of remibrutinib in adult participants with severe CPUO.

The design includes 4 periods, for a total duration of up to 60 weeks:

  • Screening period: up to 4 weeks.
  • Double-blind treatment period (treatment period 1, TP1): 24 weeks of double-blind treatment with remibrutinib or matching placebo
  • Open-label treatment period (treatment period 2, TP2): 28 weeks of open-label treatment with remibrutinib. The participants randomized to the placebo arm will be switched to remibrutinib at Week 24.
  • Safety follow-up period: 4 weeks of treatment-free safety follow-up.

Studietype

Ingrijpend

Inschrijving (Geschat)

180

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Novartis Pharmaceuticals
  • Telefoonnummer: +41613241111

Studie Locaties

      • CABA, Argentinië, C1181ACH
        • Werving
        • Novartis Investigative Site
    • Buenos Aires
      • Caba, Buenos Aires, Argentinië, C1119ACN
        • Werving
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentinië, S2000DBS
        • Werving
        • Novartis Investigative Site
    • Ontario
      • Hamilton, Ontario, Canada, L8L 3C3
        • Werving
        • Novartis Investigative Site
    • Quebec
      • Québec, Quebec, Canada, G1W 4R4
        • Werving
        • Novartis Investigative Site
    • Fukuoka
      • Kitakyushu, Fukuoka, Japan, 8078556
        • Werving
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 2400013
        • Werving
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto, Kumamoto, Japan, 8620950
        • Werving
        • Novartis Investigative Site
    • Osaka
      • Habikino, Osaka, Japan, 5838588
        • Werving
        • Novartis Investigative Site
      • Sakai, Osaka, Japan, 5938324
        • Werving
        • Novartis Investigative Site
    • Tokyo
      • Tachikawa, Tokyo, Japan, 1900023
        • Werving
        • Novartis Investigative Site
    • Alabama
      • Cullman, Alabama, Verenigde Staten, 35058
        • Werving
        • Aller Vie Health-Cullman
        • Hoofdonderzoeker:
          • John Anderson
        • Contact:
    • Florida
    • Georgia
      • Savannah, Georgia, Verenigde Staten, 31406
        • Werving
        • Aeroallergy Research Laboratories
        • Hoofdonderzoeker:
          • Brad Goodman
        • Contact:
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46256
        • Werving
        • Dawes Fretzin Clinical Rea Group
        • Hoofdonderzoeker:
          • Kenneth Dawes
        • Contact:
      • New Albany, Indiana, Verenigde Staten, 47150
        • Werving
        • Southern IN Clinical Trials
        • Contact:
        • Hoofdonderzoeker:
          • Megan Landis
    • New York
      • The Bronx, New York, Verenigde Staten, 10455
    • Ohio
      • Boardman, Ohio, Verenigde Staten, 44512
        • Werving
        • Optima Research-Boardman
        • Hoofdonderzoeker:
          • Patrick Shannon
        • Contact:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15241
        • Werving
        • Allergy and Clinical Immunology Associates
        • Hoofdonderzoeker:
          • Michael Palumbo
        • Contact:
    • South Carolina
      • North Charleston, South Carolina, Verenigde Staten, 29420
        • Werving
        • National Allergy and Asthma Research LLS
        • Hoofdonderzoeker:
          • John T Ramey
        • Contact:
    • Texas
      • Pflugerville, Texas, Verenigde Staten, 78660
        • Werving
        • Austin Inst for Clinical Research
        • Hoofdonderzoeker:
          • Edward Lain
        • Contact:
      • Seoul, Zuid -Korea, 03722
        • Werving
        • Novartis Investigative Site
      • Seoul, Zuid -Korea, 07804
        • Werving
        • Novartis Investigative Site
    • Gyeonggi-do
      • Ansan, Gyeonggi-do, Zuid -Korea, 15355
        • Werving
        • Novartis Investigative Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Key Inclusion Criteria:

  • Participant must be ≥ 18 years of age, at the time of signing the informed consent.
  • Participants with chronic pruritus for at least 4 months prior to screening.
  • Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (e.g., excluding chronic pruritus related to primary dermatological or systemic conditions, neuropathic or psychogenic origin or secondary to drugs or other allergen exposures).
  • Chronic pruritus must affect at least 2 of the following body areas: trunk, arms, or legs (cannot be unilateral and/or dermatomal in distribution).
  • Participants with ongoing, severe chronic pruritus despite the use of emollients and who are candidates for systemic therapy.
  • Participants must have severe itch defined by a WI-NRS ≥7 at screening; score scale ranges from 0 to 10; higher score indicates worse itch.
  • Participants must have an average WI-NRS ≥7 over the 7 days prior to randomization/baseline visit.
  • The average WI-NRS score over the preceding 7 days prior to the randomization/baseline visit will be calculated based on the daily WI-NRS scores (0-10).
  • Participants must have PGIS of pruritus scored as 3 "severe" at screening and baseline visits.

Key Exclusion Criteria:

  • Any active skin conditions (e.g., atopic dermatitis, psoriasis, etc.) that may interfere with the assessment of CPUO.
  • Known systemic condition(s) or medication(s) that are considered by the investigator to be the primary cause of current pruritus.
  • Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include but are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected HIV infection.
  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • Significant bleeding risk or coagulation disorders. History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAIDs), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion). Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
  • History or current hepatic disease, including but not limited to, acute or chronic hepatitis, cirrhosis or hepatic failure or aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Remibrutinib

Remibrutinib film coated tablets

Oral administration of remibrutinib

Andere namen:
  • LOU064
Experimenteel: Placebo followed by remibrutinib

Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib).

Oral administration of remibrutinib

Andere namen:
  • LOU064

Oral administration of matching placebo.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS)
Tijdsspanne: Baseline, Week 12

The WI-NRS is a patient-reported outcome (PRO) instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity.

Baseline, Week 12

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of participants achieving ≥4 point reduction from baseline in WI NRS
Tijdsspanne: Baseline, Week 4

The WI-NRS is a PRO instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity.

Baseline, Week 4
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)
Tijdsspanne: Week 12

The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome.

Week 12
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)
Tijdsspanne: Week 24

The PGIS of pruritus is a PRO measure consisting of a single item that captures the participant's overall self-assessment of the severity of their pruritus (itch) over a defined recall period. The score range is from 0 (none) to 3 (severe). Lower scores indicate better outcome.

Week 24
Change from baseline in Pruritus-related Sleep Disturbance Numerical Rating Scale (SD-NRS)
Tijdsspanne: Week 12

The SD-NRS is a PRO instrument used to assess the degree of sleep disturbance caused by pruritus (itch). The score range is from 0 (No sleep disturbance) to 10 (Worst possible sleep disturbance). Higher scores indicate greater sleep disturbance due to pruritus.

Week 12
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: Up to Week 52

Number of participants with AEs and SAEs.

Up to Week 52

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 augustus 2026

Primaire voltooiing (Geschat)

19 december 2029

Studie voltooiing (Geschat)

15 april 2030

Studieregistratiedata

Eerst ingediend

7 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

7 juli 2026

Eerst geplaatst (Werkelijk)

13 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

6 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • CLOU064R12301
  • 2025-524497-41 (Andere identificatie: EU CTIS number)
  • 2025 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren